Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01718743 · OUTCOME

Progression-free Survival

Ixazomib Citrate and Lenalidomide After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma · Source last updated 2025-01-28

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
Months
Interval / dispersion
95% Confidence Interval
Time frame
Time from autologous stem cell transplant (ASCT) to time of clinical progression or death or the time of last contact, assessed up to 30 days after completion of study treatment

What was measured

Monitored using the method of Thall et al. Estimated using the Kaplan-Meier method. Log-rank test will be performed to test the difference in time-to-event distributions between patient groups. Cox proportional hazards model will be used to include multiple covariates in the time-to-event analysis.

Analysis population: The upper bound of the 95% CI has not been reached.

Groups in this outcome

Treatment (Ixazomib Citrate, Lenalidomide)

Beginning 60-180 days post-transplant, participants receive ixazomib citrate PO on days 1, 8, and 15 and lenalidomide PO on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Ixazomib Citrate: Given PO Lenalidomide: Given PO Questionnaire Administration: Ancillary studies

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Treatment (Ixazomib Citrate, Lenalidomide)64

Reported measurements

Source class 1
Values in Months · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Treatment (Ixazomib Citrate, Lenalidomide)73.3Not reported59.9NAThe upper bound of the 95% CI has not been reached.
Complete source fields
classes
  1. categories
    1. measurements
      1. comment
        The upper bound of the 95% CI has not been reached.
        group Id
        OG000
        lower Limit
        59.9
        upper Limit
        NA
        value
        73.3
denoms
  1. counts
    1. group Id
      OG000
      value
      64
    units
    Participants
description
Monitored using the method of Thall et al. Estimated using the Kaplan-Meier method. Log-rank test will be performed to test the difference in time-to-event distributions between patient groups. Cox proportional hazards model will be used to include multiple covariates in the time-to-event analysis.
dispersion Type
95% Confidence Interval
groups
  1. description
    Beginning 60-180 days post-transplant, participants receive ixazomib citrate PO on days 1, 8, and 15 and lenalidomide PO on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Ixazomib Citrate: Given PO Lenalidomide: Given PO Questionnaire Administration: Ancillary studies
    id
    OG000
    title
    Treatment (Ixazomib Citrate, Lenalidomide)
param Type
MEDIAN
population Description
The upper bound of the 95% CI has not been reached.
reporting Status
POSTED
time Frame
Time from autologous stem cell transplant (ASCT) to time of clinical progression or death or the time of last contact, assessed up to 30 days after completion of study treatment
title
Progression-free Survival
type
PRIMARY
unit Of Measure
Months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice